论文部分内容阅读
目的：探讨不同免疫次数及不同免疫原，对接受主动免疫治疗的原发性习惯性流产患者妊娠成功率的影响。方法：对３８例有习惯性流产史的接受淋巴细胞主动免疫治疗的孕妇，进行回顾性分析。结果：接受２次主动免疫治疗的患者，妊娠成功率为８７．５％（１４／１６），而接受４次免疫治疗的患者，成功率为８６．４％（１９／２２），两种疗法的成功率比较，差异无显著性。采用丈夫淋巴细胞为免疫原治疗的患者，成功率为８４．２％（１６／１９），而采用第３个体淋巴细胞为免疫原治疗的患者，成功率８９．５％（１７／１９），两组成功率比较，差异也无显著性。结论：为预防潜在的血源感染，主动免疫疗法可从４次改为２次，而免疫原可选择患者丈夫，也可采用健康的无关第３个体。
Objective: To investigate the effect of different times of immunization and different immunogens on the success rate of pregnancy in primary habitual abortion patients receiving active immunotherapy. Methods: A retrospective analysis was performed on 38 pregnant women undergoing active immunotherapy of lymphocytes with a history of habitual abortion. Results: The rate of successful pregnancy was 87.5% (14/16) in patients receiving two active immunizations, and 86.4% (19/22) in patients receiving four immunizations. Both treatments The success rate comparison, the difference was not significant. The success rate was 84.2% (16/19) in patients treated with her husband’s lymphocytes as immunogen, and 89.5% (17/19) in patients treated with the third human lymphocyte as immunogen. The success rate of the two groups, the difference was not significant. CONCLUSIONS: In order to prevent potential blood-borne infections, active immunotherapy can be changed from 4 to 2, whereas the immunogen may choose to be the husband of the patient or a third unrelated, healthy person.